Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 794 shares of Natera stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $24.79, for a total value of $19,683.26. Following the completion of the transaction, the chief executive officer now owns 9,919 shares in the company, valued at $245,892.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Steven Leonard Chapman also recently made the following trade(s):
- On Friday, March 22nd, Steven Leonard Chapman sold 384 shares of Natera stock. The shares were sold at an average price of $20.20, for a total value of $7,756.80.
Shares of Natera stock traded down $0.18 during trading on Wednesday, reaching $24.02. The company’s stock had a trading volume of 13,816 shares, compared to its average volume of 664,614. Natera Inc has a 52-week low of $11.08 and a 52-week high of $29.62. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -11.29 and a beta of 1.41. The company has a debt-to-equity ratio of 20.88, a quick ratio of 1.73 and a current ratio of 1.85.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Great West Life Assurance Co. Can boosted its stake in shares of Natera by 136.8% during the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock valued at $80,000 after purchasing an additional 3,420 shares during the period. Legal & General Group Plc boosted its position in Natera by 14.5% in the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after purchasing an additional 736 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Natera by 6.7% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock valued at $160,000 after buying an additional 717 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in Natera by 827.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 7,047 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in Natera by 431.9% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,867 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 9,636 shares during the last quarter. 80.32% of the stock is currently owned by institutional investors.
Several research analysts recently weighed in on the stock. BidaskClub upgraded shares of Natera from a “strong sell” rating to a “sell” rating in a research report on Wednesday, February 20th. Zacks Investment Research lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Saturday, February 23rd. Finally, Canaccord Genuity restated a “buy” rating and set a $25.00 price objective on shares of Natera in a research note on Monday, March 11th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $28.25.
TRADEMARK VIOLATION WARNING: “Natera Inc (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 794 Shares” was published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.wkrb13.com/2019/06/12/natera-inc-nasdaqntra-ceo-steven-leonard-chapman-sells-794-shares.html.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: What is a capital gain?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.